Due to COVID-19, new enrollment in research studies will be greatly limited.
If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry.
View the guidance for research participants for additional information.
This study enrolls adults with pancreatic cancer. The purpose of this study is to learn whether an experimental device, a Tumor Treating Fields (TTFields) device called NovoTTF-100L(P), will be safe and effective when used with gemcitabine and nab-paclitaxel (chemotherapy medications typically used to treat this cancer). Tumor Treating Fields (TTFields) are low intensity electric fields delivered with a small medical device. The fields are used on top of area on your body where your cancer is. The purpose is to disrupt the activity of dividing cancer cells. Read More
Adults ages 18+.
Diagnosed with adenocarcinoma of the pancreas (pancreatic cancer).
Interested and assigned by the investigator to have therapy with gemcitabine and nab-paclitaxel.
This study enrolls adults who have tested positive for COVID-19 and are currently hospitalized. The purpose of this study is to learn whether giving donor plasma collected from patients who have recovered from COVID-19 infection to those who are having symptoms now helps with recovery. Read More
Adults ages 18+.
SARS-CoV-2 positive test within the past 14 days.
Currently hospitalized or in an emergency department with anticipated hospitalization.
Symptoms of acute respiratory infection.
This study enrolls adults who have tinnitus (constant ringing in the ears) or hyperacusis ( abnormally low loudness tolerance). The purpose of this study is to learn more about the connection between tinnitus (a ringing in the ears), hyperacusis (noise sensitivity) and cognition (how people think). Read More
This study enrolls people with TRK fusion cancer. The purpose of this study is to learn more about the effectiveness of the drug VITRAKVI (generic name: larotrectinib) for TRK fusion cancer that has spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. Read More
Patients with TRK fusion cancer (locally advanced or metastatic solid tumor harboring an NTRK gene fusion).
Your physician has decided to treat you with larotrectinib.